Research Keyword: drug bioavailability

Chaga mushroom triterpenoids as adjuncts to minimally invasive cancer therapies: A review

mycolabadmin

Chaga mushroom, a fungus that grows on birch trees, contains special compounds called triterpenoids that can kill cancer cells in laboratory tests. Some of these compounds, particularly inotodiol and betulinic acid, show anti-cancer activity similar to or better than conventional chemotherapy drugs. While promising, researchers need to improve how these compounds are absorbed in the body and test them more thoroughly in animals and humans before they can be used clinically.

Read More »

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A 28-year-old woman developed a fungal infection called histoplasmosis after having a tooth extracted, with the infection spreading to her lungs and sinuses. She was initially given a common antifungal medication called itraconazole, but her condition continued to worsen despite increasing the dose. When doctors switched her to a stronger medication called liposomal amphotericin B given intravenously, she improved dramatically and recovered fully. This case shows the importance of recognizing when a standard fungal treatment is not working and switching to more aggressive therapy.

Read More »

Research Progress of Polysaccharide-Gold Nanocomplexes in Drug Delivery

mycolabadmin

Scientists are combining polysaccharides (natural compounds found in plants and organisms) with tiny gold particles to create better drug delivery systems. These hybrid nanoparticles can transport medicines directly to cancer cells while reducing side effects and improving treatment effectiveness. The review discusses how these gold-polysaccharide combinations can also fight bacteria and viruses, making them useful for various medical applications beyond cancer therapy.

Read More »

Graphene nanomaterials: A new frontier in preventing respiratory fungal infections

mycolabadmin

Fungal lung infections are a serious problem, especially for people with weak immune systems. Researchers are exploring graphene nanomaterials as a new treatment approach that can deliver antifungal drugs directly to infected areas in the lungs. These tiny particles work by creating toxic stress inside fungal cells and breaking down their protective biofilms, while using smaller drug doses and causing fewer side effects than traditional treatments.

Read More »

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A healthy 28-year-old woman developed a serious fungal infection caused by Histoplasma capsulatum after dental surgery. The standard antifungal medication (itraconazole) did not work for her, even at high doses. Doctors successfully treated her with a more powerful antifungal drug called liposomal amphotericin B, which cleared the infection completely. This case shows the importance of adjusting treatment when patients don’t respond to initial therapy.

Read More »

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A 28-year-old woman developed a serious fungal infection (histoplasmosis) after dental surgery that was initially misdiagnosed as a bacterial infection. Although she was treated with an antifungal medication called itraconazole, her condition worsened with larger lung lesions appearing. When switched to a stronger intravenous antifungal called liposomal amphotericin B, she rapidly improved and fully recovered, demonstrating the importance of adjusting treatment when patients don’t respond as expected.

Read More »
Scroll to Top